Cargando…
Improved CAR-T cell activity associated with increased mitochondrial function primed by galactose
CD19 CAR-T cells have led to durable remissions in patients with refractory B-cell malignancies; nevertheless, most patients eventually relapse in the long term. Many interventions aimed at improving current products have been reported, with a subset of them focusing on a direct or indirect link to...
Autores principales: | Gross, Golda, Alkadieri, Suha, Meir, Amilia, Itzhaki, Orit, Aharony-Tevet, Yarden, Yosef, Shahar Ben, Zenab, Angi, Shbiro, Liat, Toren, Amos, Yardeni, Tal, Jacoby, Elad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557609/ https://www.ncbi.nlm.nih.gov/pubmed/37808778 http://dx.doi.org/10.1101/2023.09.23.559091 |
Ejemplares similares
-
Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia
por: Rozenbaum, Meir, et al.
Publicado: (2020) -
Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients
por: Itzhaki, Orit, et al.
Publicado: (2020) -
P520: POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION
por: Danylesko, Ivetta, et al.
Publicado: (2023) -
Impact of cryopreservation on CAR T production and clinical response
por: Brezinger-Dayan, Karin, et al.
Publicado: (2022) -
Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies
por: Beider, Katia, et al.
Publicado: (2022)